awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q40663445-48049B47-6C03-4981-BCD9-94A386161DBF
Q40663445-48049B47-6C03-4981-BCD9-94A386161DBF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40663445-48049B47-6C03-4981-BCD9-94A386161DBF
Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
P2860
Q40663445-48049B47-6C03-4981-BCD9-94A386161DBF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q40663445-48049B47-6C03-4981-BCD9-94A386161DBF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0e4df7645a8aea92d051cba700f175d455c602d5
P2860
A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.